1. |
|
|
2. |
|
|
3. |
|
|
4. |
|
|
5. |
|
|
6. |
|
|
7. |
|
|
8. |
|
|
9. |
|
|
10. |
|
|
11. |
|
|
12. |
|
|
13. |
|
|
14. |
|
|
15. |
|
|
16. |
|
|
17. |
- O'Grady, J, et al.
(författare)
-
Tuberculosis in prisons: anatomy of global neglect
- 2011
-
Ingår i: The European respiratory journal. - : European Respiratory Society (ERS). - 1399-3003 .- 0903-1936. ; 38:4, s. 752-754
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
|
|
18. |
|
|
19. |
- Pasetto, A, et al.
(författare)
-
Generation of T-cell receptors targeting a genetically stable and immunodominant cytotoxic T-lymphocyte epitope within hepatitis C virus non-structural protein 3
- 2012
-
Ingår i: The Journal of general virology. - : Microbiology Society. - 1465-2099 .- 0022-1317. ; 93:Pt 2, s. 247-258
-
Tidskriftsartikel (refereegranskat)abstract
- Hepatitis C virus (HCV) is a major cause of severe liver disease, and one major contributing factor is thought to involve a dysfunction of virus-specific T-cells. T-cell receptor (TCR) gene therapy with HCV-specific TCRs would increase the number of effector T-cells to promote virus clearance. We therefore took advantage of HLA-A2 transgenic mice to generate multiple TCR candidates against HCV using DNA vaccination followed by generation of stable T-cell–BW (T-BW) tumour hybrid cells. Using this approach, large numbers of non-structural protein 3 (NS3)-specific functional T-BW hybrids can be generated efficiently. These predominantly target the genetically stable HCV genotype 1 NS31073–1081 CTL epitope, frequently associated with clearance of HCV in humans. These T-BW hybrid clones recognized the NS31073 peptide with a high avidity. The hybridoma effectively recognized virus variants and targeted cells with low HLA-A2 expression, which has not been reported previously. Importantly, high-avidity murine TCRs effectively redirected human non-HCV-specific T-lymphocytes to recognize human hepatoma cells with HCV RNA replication driven by a subgenomic HCV replicon. Taken together, TCR candidates with a range of functional avidities, which can be used to study immune recognition of HCV-positive targets, have been generated. This has implications for TCR-related immunotherapy against HCV.
|
|
20. |
|
|
21. |
|
|
22. |
|
|
23. |
|
|
24. |
|
|
25. |
|
|
26. |
|
|
27. |
|
|
28. |
|
|
29. |
|
|
30. |
|
|
31. |
|
|
32. |
|
|
33. |
|
|
34. |
|
|
35. |
|
|
36. |
|
|
37. |
|
|
38. |
|
|
39. |
- Uhlin, M, et al.
(författare)
-
Adjunct immunotherapies for tuberculosis
- 2012
-
Ingår i: The Journal of infectious diseases. - : Oxford University Press (OUP). - 1537-6613 .- 0022-1899. ; 205205 Suppl 2, s. S325-S334
-
Tidskriftsartikel (refereegranskat)
|
|
40. |
|
|
41. |
|
|
42. |
|
|
43. |
|
|
44. |
|
|
45. |
- Zumla, A, et al.
(författare)
-
Pregnancy and infection
- 2014
-
Ingår i: The New England journal of medicine. - 1533-4406. ; 371:11, s. 1076-1076
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
|
|
46. |
|
|
47. |
|
|
48. |
|
|
49. |
|
|
50. |
|
|